Skip to main content

Aging

Strategies for Older Adults

This concerns studies into strategies specifically for older adults, but that doesn't mean other cognitive strategies can't also be useful! See also Strategies and the specific strategy pages.

See also the separate page for Mental stimulation & cognitive reserve

Older news items (pre-2010) brought over from the old website

Characteristics of age-related cognitive decline in semantic memory

A study involving 117 healthy elderly (aged 60-91) has found that, while increasing age was associated with poorer memory for names of famous people, age didn’t affect memory for biographical details about them. It also found that names served as better cues to those details than faces did. A follow-up study (to be published in Neuropsychologia) found that, in contrast, those with mild cognitive impairment and early Alzheimer’s showed not only an increased inability to remember names, but also a decline in memory for biographical details.

Langlois, R., Fontaine, F., Hamel, C., & Joubert, S. (2009). [The impact of aging on the ability to recognize famous faces and provide biographical knowledge of famous people]. Canadian Journal on Aging = La Revue Canadienne Du Vieillissement, 28(4), 337-345. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/19925699

http://www.eurekalert.org/pub_releases/2009-12/uom-whn121809.php

Rote learning may improve verbal memory in seniors

A study involving 24 older adults (aged 55—70) has found that six weeks of intensive rote learning (memorizing a newspaper article or poem of 500 words every week) resulted in measurable changes in N-acetylaspartate, creatine and choline, three metabolites in the brain that are related to memory performance and neural cell health, in the left posterior hippocampus — but only after a six-week rest period, at which time the participants also showed improvements in their verbal and episodic memory, and also only in one of the two learning groups. The group that didn’t show any change were said to have low compliance with the memorization task.

McNulty, J. et al. The Identification of Neurometabolic Sequelae Post-learning Using Proton Magnetic Resonance Spectroscopy. Presented November 26 at the annual meeting of the Radiological Society of North America (RSNA).

http://www.eurekalert.org/pub_releases/2006-11/rson-rli112206.php

Actors’ memory tricks help students and older adults

The ability of actors to remember large amounts of dialog verbatim is a marvel to most of us, and most of us assume they do by painful rote memorization. But two researchers have been studying the way actors learn for many years and have concluded that the secret of actors' memories is in the acting; an actor learning lines by focusing on the character’s motives and feelings — they get inside the character. To do this, they break a script down into a series of logically connected "beats" or intentions. The researchers call this process active experiencing, which uses "all physical, mental, and emotional channels to communicate the meaning of material to another person." This principle can be applied in other contexts. For example, students who imagined themselves explaining something to somebody else remembered more than those who tried to memorize the material by rote. Physical movement also helps — lines learned while doing something, such as walking across the stage, were remembered better than lines not accompanied with action. The principles have been found useful in improving memory in older adults: older adults who received a four-week course in acting showed significantly improved word-recall and problem-solving abilities compared to both a group that received a visual-arts course and a control group, and this improvement persisted four months afterward.

Noice, H., & Noice, T. (2006). What Studies of Actors and Acting Can Tell Us About Memory and Cognitive Functioning. Current Directions in Psychological Science, 15(1), 14-18. Retrieved from http://dx.doi.org/10.1111/j.0963-7214.2006.00398.x

http://www.eurekalert.org/pub_releases/2006-01/aps-bo012506.php

'Imagination' helps older people remember to comply with medical advice

A new study suggests a way to help older people remember to take medications and follow other medical advice. Researchers found older adults (aged 60 to 81) who spent a few minutes picturing how they would test their blood sugar were 50% more likely to actually do these tests on a regular basis than those who used other memory techniques. Participants were assigned to one of three groups. One group spent one 3-minute session visualizing exactly what they would be doing and where they would be the next day when they were scheduled to test their blood sugar levels. Another group repeatedly recited aloud the instructions for testing their blood. The last group were asked to write a list of pros and cons for testing blood sugar. All participants were asked not to use timers, alarms or other devices. Over 3 weeks, the “imagination” group remembered 76% of the time to test their blood sugar at the right times of the day compared to an average of 46% in the other two groups. They were also far less likely to go an entire day without testing than those in the other two groups.

Liu, L. L., & Park, D. C. (2004). Aging and medical adherence: the use of automatic processes to achieve effortful things. Psychology and Aging, 19(2), 318-325. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/15222825

http://www.eurekalert.org/pub_releases/2004-06/nioa-ho060104.php

How to benefit from memory training

Brain and memory training programs are increasingly popular, but they don't work well for everyone. In particular, they tend to be much less effective for those who need them the most — those 80 and older, and those with lower initial ability. But a new study shows the problem is not intrinsic, but depends on the strategies people use.  The study found that people in their 60s and 70s used a strategy of spending most of their time on studying the materials and very little on the test, and showed large improvements over the testing sessions. By contrast, most people in their 80s and older spent very little time studying and instead spent most of their time on the test. These people did not do well and showed very little improvement even after two weeks of training.

Bissig, D., & Lustig, C. (2007). Who Benefits From Memory Training? Psychological Science, 18, 720-726. Retrieved from http://www.ingentaconnect.com/content/bpl/psci/2007/00000018/00000008/art00013

http://www.eurekalert.org/pub_releases/2007-08/uom-dpt082007.php

Inflammation in Alzheimer's

Older news items (pre-2010) brought over from the old website

Evidence challenges inflammation theory for Alzheimer's

Although it has long been theorized that inflammation plays a role in the development of Alzheimer’s, repeated studies have failed to find consistent evidence that anti-inflammatory drugs are helpful. Now a brain tissue study reveals that supporting brain cells called microglia are not activated in the presence of tau tangles in the brains of Alzheimer’s patients, as has been predicted, and as would be the case if there were inflammation. Instead, microglia are degenerating. It’s suggested that it is this loss of microglia that contributes to the loss of neurons, and thus to the development of dementia. The next step is to find out why the microglia are dying.

Streit, W.J. et al. 2009. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer’s disease. Acta Neuropathologica, Published online ahead of print.

http://www.eurekalert.org/pub_releases/2009-06/uof-pat061509.php

Blood inflammation plays role in Alzheimer's disease

Data from the Framingham Heart Study has found that those with the highest amount of cytokines (protein messengers that trigger inflammation) in their blood were more than twice as likely to develop Alzheimer's disease as those with the lowest amount of cytokines, providing further evidence that inflammation plays a role in the development of Alzheimer's disease.

Tan, Z.S. et al. 2007. Inflammatory markers and the risk of Alzheimer disease: The Framingham Study. Neurology, 68, 1902-1908.

http://www.eurekalert.org/pub_releases/2007-05/aaon-bip052107.php

Alzheimer's disease linked to early inflammation

A new study of dementia in identical twins suggests that exposure to inflammation early in life quadruples one's risk of developing Alzheimer's disease. The study involved sifting the 20,000 participants in the Swedish Twin Registry for the 109 "discordant" pairs where only one twin had been diagnosed with dementia. Answers to health questions in the survey enabled the researchers to build a crude indicator of periodontal disease, measured indirectly by teeth lost or loose. Because this is not a direct measure of inflammation, the results need to be confirmed, but they do suggest that an inflammatory burden early in life, as represented by chronic gum disease, may have severe consequences later. The study also found that mental activities at age 40 did not seem to lower the risk of developing Alzheimer's, and the level of education was not a large factor once genes were taken into account (nevertheless, those with less high school and college education had 1.6 times the risk of dementia). Previous studies have shown that Alzheimer's is strongly genetic: If one twin has the disease, his or her identical twin has a 60% chance of developing it.

The study was presented at the first Alzheimer's Association International Conference on Prevention of Dementia, to be held June 18-21 in Washington, D.C.

http://www.eurekalert.org/pub_releases/2005-06/uosc-adl061605.php

Antibody detection in Alzheimer's may improve diagnosis, treatment

A study has found that people with Alzheimer’s disease have three to four times more antibodies to RAGE (receptor for advanced glycation end products) and beta amyloid — both major players in Alzheimer’s — than their healthy counterparts. The ability to measure these specific antibody levels could lead to a method for very early diagnosis. The finding may also point to a new treatment approach. The study supports the theory that autoimmunity and resulting inflammation play a big role in Alzheimer’s.

Mruthinti, S., Buccafusco, J.J., Hill, W.D., Waller, J.L., Jackson, T.W., Zamrini, E.Y. & Schade, R.F. 2004. Autoimmunity in Alzheimer’s disease: increased levels of circulating IgGs binding Ab and RAGE peptides. Neurobiology of Aging, 25 (8), 1023-1032.

http://www.eurekalert.org/pub_releases/2004-06/mcog-adi060204.php

A new hypothesis about Alzheimer's

A new theory about the cause of Alzheimer's disease has been proposed. According to this theory, Alzheimer’s arises as a consequence of inflammation, which creates abnormal metabolites out of normal brain molecules. These abnormal metabolites then modify "amyloid beta" proteins in the brain and cause them to misfold, thus accumulating into the fibrils and plaques characteristic of the disease. The inflammation process that creates these metabolites can be triggered by numerous stimuli, including infections that precede the onset of Alzheimer's disease by a significant amount of time — perhaps years. Traumatic head injuries, for example, are a major risk factor for later developing Alzheimer's disease. Inflammation is increasingly seen as playing a role in neurodegenerative diseases.

Zhang, Q., Powers, E.T., Nieva, J., Huff, M.E., Dendle, M.A., Bieschke, J., Glabe, C.G., Eschenmoser, A., Wentworth, P.Jr., Lerner, R.A. & Kelly, J.W. 2004. Metabolite-initiated protein misfolding may trigger Alzheimer's disease. Proceedings of the National Academy of Sciences, 101 (14), 4752-7.

http://www.eurekalert.org/pub_releases/2004-03/sri-anh031504.php

Statins

Older news items (pre-2010) brought over from the old website

Statins may protect against memory loss

The question of whether statins protect against dementia and memory loss bounces back and forth. In the latest study — lasting 5 years and involving 1674 older adults who were dementia-free at the start of the study but were considered high risk — it was found that those who took statins (27%) were about half as likely to develop dementia as those who didn’t take them. Statins lowered the risk of dementia in all participants, but the statins had more of an impact on the group at high risk due to metabolic syndrome.

Cramer, C. et al. 2008. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology, 71, 344-350.

http://www.eurekalert.org/pub_releases/2008-07/aaon-smp072208.php
http://www.eurekalert.org/pub_releases/2008-07/uom-smp072308.php

Cholesterol-lowering drugs may not prevent Alzheimer's disease

Research on the protective benefit or otherwise of taking statins has been contradictory to date. Now new results from the long-running Religious Orders Study has come down on the side of no benefit. The study found no relation between statin use and Alzheimer’s, and no association between taking statins and a slower cognitive decline among older people.

Arvanitakis, Z., Schneider, J.A., Wilson, R.S., Bienias, J.L., Kelly, J.F., Evans, D.A. & Bennett, D.A. 2008. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology, first published on January 16, 2008 as doi: doi:10.1212/01.wnl.0000288181.00826.63

http://www.eurekalert.org/pub_releases/2008-01/aaon-cdm010808.php

Statin treatment improves spatial memory in Alzheimer's mice

Treatment with the cholesterol-lowering statin drug Simvastatin significantly improved spatial in mice genetically bred to have an Alzheimer’s-like disease. The benefits were more pronounced in males. Levels of nNOS (neuronal nitric oxide synthase) levels were significantly higher in the hippocampus and cortex of statin treated groups as compared to similar mice that did not receive statin. nNOS is responsible for the release of nitric oxide, a substance that causes dilation of the blood vessels in the brain, thus increasing blood flow.

The findings were presented April 30 at Experimental Biology 2007 in Washington, DC.

http://www.eurekalert.org/pub_releases/2007-04/foas-sti042107.php

Cholesterol treatment, including statins, may slow Alzheimer's disease progression

A study following 342 Alzheimer’s patients attending a memory clinic for almost three years has found that the disease progressed significantly more slowly in patients given cholesterol lowering drugs. A larger trial will be needed to confirm the findings.

Masse, I., Bordet, R., Deplanque, D., Al Khedr, A., Richard, F., Libersa, C. & Pasquier, F. 2005. Lipid lowering agents are associated with a slower cognitive decline in Alzheimer’s disease. Journal of Neurology Neurosurgery and Psychiatry, 76, 1624-1629.

http://www.eurekalert.org/pub_releases/2005-11/bsj-cti111605.php

No clear-cut answers on statins as therapy for Alzheimer's disease

A study with genetically engineered mice found that those treated with simvastatin regained their ability to navigate mazes and that the drug improved performance even for the non-engineered mice in the control group.
Another study found that four different statins reduced, to varying extent, brain cells' production of a protein fragment thought to play a key role in Alzheimer's, with fluvastatin (Lescol, Novartis) being the most effective.
However, a review of all existing randomized controlled trials of statins in people without dementia (comprising over 30,000 participants) found no evidence yet that any statin protects against cognitive decline. In a second, small study of elderly people at risk for dementia, rates of brain tissue shrinkage, measured using a special MRI scan, were no different between statin users and nonusers.
New results from three, long-running population studies that assess the possible impact of statins on preventing Alzheimer's suggest that the benefit of statins in warding off dementia largely disappears if patients are followed for several years. There are a number of large-scale clinical trials underway to try and resolve this issue.

Presented at the 9th International Conference on Alzheimer's Disease and Related Disorders (ICAD), July 17-22, 2004, in Philadelphia, Pennsylvania.
Ling Li – Enhancement of Learning and Memory by Statins Beyond Alzheimer's Disease (O4-05-01, Wed., 7/21, 3-5 pm)
Richard Parsons – Statins Reduce Beta-amyloid Production but Increase its Release From the Cell (P4-362, Wed., 7/21, 12:30 pm)
Kina Hoglund – The Effect of Simvastatin Treatment on the Processing of the Amyloid Precursor Protein in Patients with Alzheimer's Disease (P4-386, Wed., 7/21, 12:30 pm)
P. Murali Doraiswamy – Statin Use and Hippocampal Volume in Subjects at Risk for Alzheimer's Disease (O1-02-08, Sun., 7/18, 4-6 pm)
John Breitner – Can statins prevent AD, or are they just prescribed less often to those with cognitive disorders? (S1-03-01, Sun., 7/18, 1:45 pm)

http://www.eurekalert.org/pub_releases/2004-07/aa-nca070804.php

Cholesterol-lowering drugs shown to decrease predictor of Alzheimer's

In a recent study, cholesterol-lowering medications known as statins lowered brain cholesterol levels in Alzheimer’s patients by 21.4%. Brain cholesterol is involved in the formation of amyloid plaques. The findings from this research provide information about the safety and efficacy of a reasonable dose of a statin on the reduction of brain cholesterol, and pave the way for research to find out what effect statins have on the cognitive impairment of people with Alzheimer’s.

Vega, G.L., Weiner, M.F., Lipton, A.M., von Bergmann, K., Lütjohann, D., Moore, C. & Svetlik, D. 2003. Reduction in Levels of 24S-Hydroxycholesterol by Statin Treatment in Patients With Alzheimer Disease. Archives of Neurology, 60, 510-515.

http://www.eurekalert.org/pub_releases/2003-04/uots-cds041703.php

Statins may prevent damage by Alzheimer's disease protein

Recently, the risk of developing Alzheimer's disease has been shown to be reduced in people treated with statins (cholesterol-lowering drugs). A new study has found that statins appear to block the vasoconstrictive effects of the A-beta protein (involved in Alzheimer's disease). It is perhaps the anti-inflammatory properties of these drugs (rather than their role in lowering cholesterol) that helps protect against dementia.

Paris, D., Townsend, K.P., Humphrey, J., Obregon, D.F., Yokota, K. & Mullan, M. 2002. Statins inhibit Ab-neurotoxicity in vitro and Ab-induced vasoconstriction and inflammation in rat aortae. Atherosclerosis, 161(2), 293-299.

http://www.eurekalert.org/pub_releases/2002-04/uosf-smp040102.php

Forgetfulness in old age may be related to changes in retrieval strategy

Evidence is accumulating that age-related cognitive decline is rooted in three related factors: processing speed slows down (because of myelin degradation); the ability to inhibit distractions becomes impaired; working memory capacity is reduced.

A new study adds to this evidence by looking at one particular aspect of age-related cognitive decline: memory search.

Why learning gets harder as we get older

A new study adds more support to the idea that the increasing difficulty in learning new information and skills that most of us experience as we age is not down to any difficulty in acquiring new information, but rests on the interference from all the old information.

Hearing loss accelerates cognitive decline in older adults

I’ve written before about the gathering evidence that sensory impairment, visual impairment and hearing loss in particular, is a risk factor for age-related cognitive decline and dementia. Now a large long-running study provides more support for the association between hearing loss and age-related cognitive decline.

Dopamine decline underlies episodic memory decline in old age

The neurotransmitter dopamine is found throughout the brain and has been implicated in a number of cognitive processes, including memory. It is well-known, of course, that Parkinson's disease is characterized by low levels of dopamine, and is treated by raising dopamine levels.